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Hematological abnormalities are common manifestations of
HIV infection that are regularly encountered in the clinical
setting. Although initially recognized with the ﬁrst descrip-
tions of HIV infection over 30 years ago, our understanding
of the epidemiology, natural history, and treatment of these
blood disorders continues to evolve. Aggressive lymphomas
such as diﬀuse large B-cell lymphoma and primary CNS
lymphoma have decreased since the introduction of combi-
nationantiretroviraltherapy(cART),thoughtheseandother
HIV-associated malignancies continue to a have a major
impact on the morbidity and mortality of persons with
HIV. Other blood disorders frequently associated with HIV
include cytopenias, particularly anemia and thrombocytope-
nia. In this special issue, studies investigating hematologic
diseases associated with HIV infection are discussed. The
diagnosis, treatment, and prognosis of Hodgkin lymphoma
(HL) in the era of cART are reviewed by Jacobson and
Abramson. Unlike non-Hodgkin lymphomas (NHL), the
incidence of HL in HIV-infected patients has not decreased
in the cART era. However, the introduction of cART has
allowed the delivery of full doses of chemotherapy with
signiﬁcantly improved outcomes. Despite these advances,
patientswithHIV-associatedHLremainatriskoftreatment-
related toxicity, and interactions between antiretroviral and
chemotherapeutic agents necessitate careful attention to
supportive care.
Two papers focus on HIV-associated Burkitt lymphoma
(BL). Though the outcome of HIV-NHL has improved
substantially in the cART era, the outcome of HIV-BL with
standard chemotherapy remains poor. J. A. Rodrigo et al.
describe the combined experience in four Canadian centers
treating patients with HIV-BL with the CODOX-M/IVAC
regimenwithorwithoutrituximabinthemodernera.Inthis
study, intensive chemotherapy with CODOX-M/IVAC ± R
yielded acceptable toxicity and favorable survival rates. A.
M. Petrich et al. review the larger picture in the treatment
of HIV-BL in the paper entitled “paradigms and controversies
in the treatment of HIV-related Burkitt lymphoma.” In this
paper, available data on the treatment of patients with HIV-
BL with current BL-directed chemotherapy regimens are
discussed in detail, including Hyper-CVAD, dose-adjusted
EPOCH, the PETHEMA regimen, and CODOX-M/IVAC.
Areas of uncertainty in the treatment of these patients
includetheadditionofrituximabtochemotherapyregimens,
the optimal approach to patients with relapsed or refractory
BL and the role of stem cell transplantation, the appropriate
approach to older patients and patients with central nervous
system involvement, and the role of antiretroviral therapy
and supportive care.
An intriguing and pressing challenge in the management
of patients with both malignant and nonmalignant hema-
tologic disorders in HIV infection is the optimal approach
to be taken in the developing world. This topic is addressed
by M. Ulrickson et al. in the paper “Epidemiology, diagnosis,
and treatment of HIV-associated NHL in resource-limited
settings.” The epidemiology of NHL in Africa is compared
to that of the US, and discrepancies in survival highlighted
by cancer registries are discussed. Challenges in managing
patients with NHL in resource-limited settings include
diagnostic challenges due to limited access to a full battery
of immunohistochemical tests and limited molecular testing.2 Advances in Hematology
Treatment challenges include limited access to antiretro-
viral regimens, prophylactic agents, IV infusion centers,
and a higher incidence of major infectious complications
including tuberculosis and hepatitis B. Response assessments
are further limited by a lack of ready access to cross-
sectional imaging in some regions. Despite these challenges,
progress has been made in developing tolerable and eﬀective
treatment regimens appropriate to these circumstances, and
these important advances are reviewed.
A common nonmalignant complication of HIV infection
is immune thrombocytopenia (ITP). The characteristics of
HIV-associated ITP were documented prior to the cART
era, and the optimal treatment beyond cART is unknown.
For this reason, K. L. S. Ambler et al. present a retrospec-
tive cohort study reviewing individuals with severe HIV-
associated ITP diagnosed in the cART era. Their series
is the largest such report of severe HIV-ITP in the post-
cART era. The major ﬁnding from this study was that,
althoughthevarioustreatmentswerewelltoleratedandmost
patients achieved a safe platelet count, nearly all patients
(87%)requiredretreatmentforrecurrenceofsevereITP.This
highlightsthatnewapproachestothetreatmentofITPinthis
population are needed.
The intent of this special issue was to initiate interest in
and further inquiry into the many hematologic complica-
tions faced by persons living with HIV. In addition to the
topics discussed in this issue, areas for future exploration
include the approach to management of patients with less
common lymphoproliferative disorders such as indolent
NHL, paraproteinemias, and Castleman disease, as well as
non-malignant causes of cytopenias and their management.
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